ClinicalTrials.gg
RecruitingNCT06090110RESILIENCEUpdated Aug 2, 2024

Vagal Nerve Stimulation in Irritable Bowel Syndrome

An interventional study of Vagal Nerve Stimulation and Sham stimulation in Irritable Bowel Syndrome, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-02.

Sponsored by Maastricht University Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
166
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center — 1 open to participants now, 2 under way, none of them phase 3. Irritable Bowel Syndrome · Maastricht University Medical Center.

Planned enrollment
3rd of 12
166 · median 50
Started
2023
with 1 other
No phase
8 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 14th registered.

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

1 of the 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 131 Irritable Bowel Syndrome studies recruiting now, 35 (27%) set no upper age limit and 86 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Irritable Bowel Syndrome by Maastricht University Medical Center, or all of them as a file.
02

Study summary

This randomized control trial aims to evaluate the effect of transcutaneous auricular vagal nerve stimulation in patients with irritable bowel syndrome. The intervention will be 8 weeks of treatment with a vagal nerve stimulator. The main objectives are:

  • To evaluate the clinical response, defined as a decrease of at least 50 points on the IBS-SSS questionnaire, of the treatment.
  • To ascertain whether the autonomic-vagal neurosignature, derived from pre-treatment registration of symptom profiles, autonomic responses and imaging of neuronal activity as a reaction to stress is able to predict therapeutic response to tVNS accurately.
  • To evaluate the effect of treatment on quality of life
  • To evaluate the effect of treatment on depression
  • To evaluate the effect of treatment on anxiety Participants will be asked to wear a wearable (Fitbit) and fill out a daily questionnaire for one week. Thereafter, a functional brain MRI will be performed.

In the intervention group patients will receive transcutaneous nerve stimulation for 8-weeks at home. The comparison group will receive the same device but with a non-conducting electrode.

Patients fill out weekly questionnaires during the treatment period and at follow-up moments 3 and 6 months after finishing the treatment period.

03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • vagal nerve stimulation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of IBS according to Rome IV criteria (3), as follows:
  • Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with 2 or more of the following criteria:
  • Related to defecation.
  • Associated with a change in stool frequency.
  • Associated with a change in stool from (appearance).
  • Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis.
  • Age between 18 and 75 years;
  • Ability to understand and speak the Dutch language.
  • Ability to understand how to utilize the ESM application.

Exclusion criteria

Exclusion Criteria:

  • A history of abdominal surgery, except for uncomplicated appendectomy, laparoscopic cholecystectomy and hysterectomy is present or otherwise based on the principal investigator's judgement.
  • Presence of metallic prostheses, pacemakers, metal clips on blood vessels, metal parts in the eye, an intrauterine device (with the exception of the Mirena IUD), metal braces, facial tattoos and/or metal objects.
  • History of major head trauma or head/brain surgery
  • History of claustrophobia
  • Pregnancy, lactation, intention to become pregnant during the study period
  • Students and employees of Maastricht University are not precluded from participation, unless they have a direct personal, professional or hierarchical position with regards to any of the study team members or their department.
  • If the subject has a cardiac arrhythmia, the attending physician will be consulted before participation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
166 participants (estimated)

Study arms

  • Active comparator
    Intervention

    transcutaneous auricular vagal nerve stimulation, for 8 weeks at least one hour a day

    Device: Vagal Nerve Stimulation

  • Placebo comparator
    placebo

    sham stimulation with a non-conducting electrode, for 8 weeks at least one hour a day

    Device: Sham stimulation

Interventions

  • DeviceVagal Nerve Stimulation

    Transcutaneous Auricular Vagal Nerve Stimulation

  • DeviceSham stimulation

    Sham stimulation with a non-conduction electrode

06

What researchers measure

Primary outcomes

  1. Clinical meaningful decrease in severity of GI-symptoms

    Measuring IBS-SSS, defined as a decrease of at least 50 points

    Time frame: at the end of the 8 week treatment period

Secondary outcomes

  1. Predictive value of neuro-signature

    The value of the multimodal neuro-signature in the prediction of clinical response to tVNS in IBS-patients.

    Time frame: at the end of the 8 week treatment period

  2. adverse events

    Number and severity of adverse events

    Time frame: at the end of the 8 week treatment period

  3. Anxiety/depression

    Symptoms of anxiety and depression measured using PHQ-9 and GAD-7

    Time frame: at the end of the 8 week treatment period

  4. Cost-effectiveness

    Direct and indirect costs made during the treatment period

    Time frame: at follow up moment 2 (6 months after 8 week treatment period)

  5. Time the device was used

    The amount of time patients used the tVNS device

    Time frame: at the end of the 8 week treatment period

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Nov 2025, 23 months after the start.

Of 308 non-industry interventional studies with no phase under Irritable Bowel Syndrome, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's planned 23 months is close to that.

Counting every sponsor, half of 360 studies reached it within 19 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2023
First posted
Oct 19, 2023
StartActual
Dec 1, 2023
Primary completionEst.
Nov 1, 2025
CompletionEst.
Nov 1, 2026
Last update
Aug 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06090110
Responsible party
Sponsor
First posted
Oct 19, 2023
Start date
Dec 1, 2023
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Aug 2, 2024

Study contacts

Kimberly Hawinkels
Contact
kimberly.hawinkels@maastrichtuniversity.nl
0883887808
Daniel Keszthelyi
principal investigator · Maastricht University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion